Dalteparin sodium for the prevention of venous thromboembolism in advanced pancreatic cancer patients undergoing chemotherapy

Trial Profile

Dalteparin sodium for the prevention of venous thromboembolism in advanced pancreatic cancer patients undergoing chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2013

At a glance

  • Drugs Dalteparin sodium (Primary)
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2013 Results presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
    • 10 Dec 2013 New trial record
    • 09 Dec 2013 Primary endpoint 'Disease-occurrence-rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top